Table 2

Patient-level outcomes for all subjects finishing the study

Subject IDSiteOL controlCLC
BG (mmol/L)% Target# HypoLBGIBG (mmol/L)% Target# HypoLBGI
MeanSDMeanSD
2310116.921.5298.0031.278.312.1376.6010.44
2310216.501.6793.9121.586.812.0487.7211.48
2310418.482.6270.9600.717.641.8887.5010.74
2310518.482.4971.5641.328.562.4565.1920.63
2310617.852.4877.6031.729.232.3760.8550.57
2320227.602.4974.1942.278.052.2282.0900.41
2320326.703.2788.1592.956.071.7988.4743.08
2320427.402.6179.6731.708.762.5078.3730.29
2330139.212.3768.0920.4610.023.5962.9400.19
23302311.692.5122.1710.149.982.3249.8910.12
2330339.142.4749.5420.6410.002.6149.0120.31
23304313.053.6020.5920.0913.363.1812.2510.02
2330538.052.5378.3051.229.202.9160.7400.77
2340149.052.2665.6810.188.942.8567.4400.44
2340249.592.3561.3610.399.183.2467.3400.64
2340347.501.9786.1311.169.702.7561.3200.27
2340446.591.7793.8301.527.952.1180.0511.17
2340548.272.8973.6200.839.521.9252.6500.02
  • Site 1, UVA; site 2, SDRI; site 3, Padova; site 4, Montpellier; % target, percentage of time within the target range of 3.9–10 mmol/L; # hypo, number of hypoglycemic episodes requiring treatment.